吡格列酮联合格列美脲治疗2型糖尿病的临床观察 |
| |
引用本文: | 唐燕,王秀凤. 吡格列酮联合格列美脲治疗2型糖尿病的临床观察[J]. 吉林医学, 2012, 33(31): 6764-6766 |
| |
作者姓名: | 唐燕 王秀凤 |
| |
作者单位: | 上海市浦东新区川沙社区卫生服务中心内科 |
| |
摘 要: | 目的:观察吡格列酮联合格列美脲治疗2型糖尿病的疗效及其对血脂的影响。方法:选择130例2型糖尿病患者,随机分为观察组和对照组,每组各65例。对照组予以吡格列酮治疗,观察组在对照组的基础上予以格列美脲治疗。观察两组空腹血糖(FPG)、空腹胰岛素(Fins)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)变化。结果:两组治疗后FBG、HbA1c、Fins和HOMA-IR水平较治疗前明显降低(P<0.01),而观察组的降低水平较对照组更为明显,差异有统计学意义(P<0.05或<0.01)。治疗后观察组的TC、TG、LDL-C和HDL-C水平较治疗前和对照组明显降低,差异有统计学意义(P<0.05或<0.01)。观察组的不良反应发生率为6.15%低于对照组的18.46%(P<0.05)。结论:吡格列酮联合格列美脲治疗2型糖尿病的疗效显著,对血脂具有调整作用,且不良反应发生率低,值得临床推荐。
|
关 键 词: | 2型糖尿病 吡格列酮 格列美脲 血脂 |
Clinical observation of pioglitazone combined with glibenclamide in patients with the type 2 diabetes |
| |
Affiliation: | TANG Yan,WANG Xiu-femg(Deparment of Internal Medicine,Chuansha Community Health Center of Shanghai Pudong New Area,Shanghai 201200,China) |
| |
Abstract: | Objective To observe the therapeutic effect of pioglitazone combined with glibenclamide in patients with the type 2 diabetes and its effects on blood lipids.Method 130 patients with type 2 diabetes from January 2010 to December 2011 were randomly divided into observation group and control group.Each group had 65 cases.The control group was given pioglitazone,and observation group was given glibenclamide on the basis of control group.The levels of fasting plasma glucose(FPG),fasting insulin(Fins),insulin resistance index(HOMA-IR),total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C) and high density changes in lipoprotein cholesterol(HDL-C) were observed in two groups.Results After treatment,the levels of FBG,HbA1c,Fins and HOMA-IR were significantly lower than those before treatment(P<0.01),while the levels of the observation group were more obvious compared with the control group,the difference was statistically significant(P<0.05 or <0.01).After treatment,the levels of TC,TG and LDL-C and HDL-C in observation group decreased significantly than those before treatment and control group,the difference was statistically significant(P<0.05 or <0.01).The incidence of adverse reactions in the observation group was 6.15%,lower than 18.46% in the control group(P<0.05).Conclusion The therapeutic effect of pioglitazone combined with glibenclamide in patients with the type 2 diabetes is obvious,which can adjust the metabolism of lipids and reduce the adverse reactions.It is worthy to recommend. |
| |
Keywords: | Type 2 diabetes Pioglitazone Glimepiride Lipids |
本文献已被 CNKI 等数据库收录! |
|